IPO Details
RHP/DRHPIssue Date
18 Jun - 20 Jun'25
Investment/lot
₹ 115200
Price Range
91 - 96
Lot Size
1200
IPO Size
₹ 58.57 cr
Schedule of Influx Healthtech IPO
Start date
18/06/2025
End date
20/06/2025
Allotment of bids
23/06/2025
Refund Initiation
24/06/2025
Listing on exchange
25/06/2025
About Influx Healthtech IPO
The IPO of Influx Healthtech Ltd comprises a fresh issue of up to 50,00,400 equity shares. It also has an offer for sale of up to 11,00,400 equity shares. The IPO is a 100% book-built offer. The price band of the IPO is between ₹91 and ₹96. The lot size of the IPO is 1200 shares.
The IPO opens on June 18, 2025 and closes on June 20, 2025. The basis of allotment will take place on June 23, 2025. The listing of the shares will take place on June 25, 2025. The credit of shares to the demat account will take place on June 24, 2025. The initiation of refunds will take place on June 24, 2025.
Objectives of Influx Healthtech IPO
- Funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division
- Funding capital expenditure requirements for setting up of manufacturing facility for Veterinary Food Division
- Purchase of machineries for Homecare and Cosmetic Division
- General corporate purposes
Influx Healthtech IPO Valuation
| Detail | Information |
|---|---|
Upper Price Band | ₹96 |
Fresh Issue | Up to 50,00,400 equity shares |
Offer for Sale | Up to 11,00,400 equity shares |
EPS in ₹ in FY 25 | 7.36 |
Influx Healthtech IPO Share Offer and Subscription Details
| Investor | Shares Offered |
|---|---|
QIBs | Not more than 50% of the net offer |
Non-institutional Applicants | Not less than 15% of the net offer |
Retail Individual Investors | Not less than 35% of the net offer |
Industry Outlook
The nutraceutical market in India is evolving and is estimated to reach USD 18 billion by the end of 2025 as compared to USD 4 billion by end of 2020. The global nutraceutical market is currently estimated at around $400 billion, blending the fields of food, pharmaceuticals, and biotechnology.
India stands out as a key player, supported by its rich heritage of traditional knowledge, especially in Ayurveda, and a unique ecosystem that fosters growth in this sector. However, India's share remains under 2% globally, primarily due to a lack of defined industry classification within Indian ministries, limiting targeted sector support.
Company Information
Influx Healthtech Ltd is a Mumbai-based, healthcare focused company specialising in contract manufacturing. Since its inception in 2020, the company has established itself as a reliable Contract Development and Manufacturing Organisation (CDMO), offering specialised services to a wide range of clients across various industries.
Its expertise spans the production of dietary and nutritional supplements, cosmetics, ayurvedic/herbal products, veterinary feed supplements, homecare products, active pharmaceutical ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables.
Strengths of Influx Healthtech
Diversified Product Portfolio
Inlfux Healthtech Ltd specialises in contract manufacturing a wide and diverse range of products, designed to cater to a broad spectrum of customer needs and preferences. Its comprehensive product portfolio includes multi-nutritional tablets, dietary supplements, various ayurvedic products, oral dispersible films, gummy candies, ice sticks, and numerous other innovative items.
This wide variety not only demonstrates its commitment to meeting diverse consumer demands but also highlights its ability to adapt and innovate across various market segments.
Diverse Clientele
The company’s diverse client base spans multiple sectors, including cosmetics, pharmaceuticals, and homecare. This broad range of industries provides it with a strategic advantage, reducing its reliance on any single customer or sector and enhancing its financial stability.
By serving a wide variety of clients, it mitigates the risks associated with shifts in customer preferences or changes in buying behaviour, ensuring that its operations remain adaptable and resilient.
Stringent Quality Assurance/Quality Control
The company is committed to maintaining the highest quality across its product offerings. It ensures the excellence of its products through a rigorous quality control mechanism at every stage of the manufacturing process. This approach is crucial to guarantee that its finished products meet the exact requirements of its customers and pass all necessary validations and quality checks.
Risks of Influx Healthtech IPO
- Downturn in Nutraceutical Industry :
Influx Healthtech Ltd is reliant on the demand from the nutraceutical industry for a significant portion of its revenue. Any downturn in the nutraceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the company’s business and results of operations.
- Concentrated Manufacturing Facility :
The company’s existing manufacturing facilities are concentrated in a single region i.e., Palghar, Thane, Maharashtra and the inability to operate and grow its business in this particular region may have an adverse effect on its business, financial condition, results of operations, cash flows and future business prospects.
- Dependence on Few Customers :
The company’s top 10 customers contributed 47.89%, 50.10% and 46.29% of its revenue from operations for the financial year ended as on March 31, 2025, March 31, 2024, and March 31, 2023 respectively. Its business operations are highly dependent on its customers and the loss of any of its customers may adversely affect its sales and consequently on its business and results of operations.
Influx Healthtech IPO Financials
Particulars (in Rs. crores)
Particulars (in Rs. crores)
Peer Comparison
| Company Name | Total Income (in ₹ crores) | EPS in ₹ | Return on Net Worth (in %) | NAV Per Share (in ₹) |
|---|---|---|---|---|
Influx Healthtech Ltd | 104.98 | 7.36 | 36.98 | 19.91 |
Sudarshan Pharma Industries Ltd | 505.38 | 0.66 | 12.45 | 5.30 |
Quest Laboratories Ltd | 108.15 | 8.28 | 16.58 | 49.92 |
Anchor Investor Bidding Date
Anchor portion of the offer opens on June 17, 2025.
IPO Registrar and Book Running Lead Manager
- IPO Registrar: Maashitla Securities Pvt Ltd
- Book Running Lead Manager: Rarever Financial Advisors Pvt Ltd
Business Model
Influx Healthtech Ltd specialise in contract manufacturing a wide range of products across various sectors, including Dietary/Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, and Homecare Products, solely serving B2B clients.
Company Growth Trajectory
The revenue from operations of Influx Healthtech Ltd grew from ₹76.0565 crores in FY 23 to ₹104.8536 crores in FY 25. The number of customers served increased from 490 in FY 23 to 571 in FY 25, while PAT margin increased from 9.46% to 12.75% during the same period.
The company’s EBITDA margin increased from 14.10% in FY 23 to 19.62% in FY 25. Diverse product portfolio and clientele have contributed to the company's growth over the years.
Market Position
Influx Healthtech Ltd operates manufacturing facilities located in Thane, Maharashtra, covering a total area of approximately 9,676 square feet, 13,000 square feet, and 14,000 square feet, respectively. These facilities are certified to international quality standards, including GMP (Good Manufacturing Practice), HACCP (Hazard Analysis & Critical Control Points), ISO 22000, and Halal certifications, ensuring adherence to the highest standards of safety, quality and regulatory compliance.
These certifications reflect the company’s adherence to stringent safety, quality, and regulatory compliance standards. Equipped with advanced machinery, a dedicated quality control department, and a skilled workforce, its facilities are designed to meet diverse customer needs efficiently and effectively
Influx Healthtech Profit and Loss
| Parameter | FY 25 | FY 24 | FY 23 |
|---|---|---|---|
Total Revenue (in ₹ crores) | 104.98 | 100.01 | 76.05 |
Profit Before Tax (in ₹ crores) | 17.87 | 14.93 | 9.73 |
Profit After Tax (in ₹ crores) | 13.36 | 11.12 | 7.19 |
EBITDA (in ₹ crores) | 20.57 | 16.95 | 10.72 |
EPS in ₹ | 7.36 | 6.13 | 3.96 |
Influx Healthtech IPO Balance Sheet
| Parameter | FY 25 | FY 24 | FY 23 |
|---|---|---|---|
Profit Before Tax (in ₹ crores) | 17.87 | 14.93 | 9.73 |
Net Cash Flow from Operating Activities (in ₹ crores) | 7.05 | 8.94 | 6.82 |
Net Cash Flow from Investing Activities (in ₹ crores) | -8.644 | -8.35 | -4.87 |
Net Cash Flow from Financing Activities (in ₹ crores) | -0.10 | -0.52 | 0.13 |
Cash & Cash Equivalents as At End of the Period (in ₹ crores) | 1.91 | 3.60 | 3.54 |
How to Apply for the Influx Healthtech IPO?
Visit the Registrar’s Website
- Visit the official website of Maashitla Securities Pvt Ltd
- Click on ‘Public Issues’ under ‘Allotment Status’
- Select ‘Company Name’ and enter either your PAN, application number or Demat account number
- Click on ‘Submit’ to know the status
Check on the National Stock Exchange Website
The National Stock Exchange (NSE) has an IPO Bid Verification module. You can use it to check the status of Influx Healthtech Ltd IPO. Go to www.nseindia.com and find the 'Invest' tab. Click on 'Verify IPO Bids' under 'Resources & Tools'.
On the NSE IPO Bid Verification page, enter:
- Company name from dropdown
- Application number
- PAN
Then click 'Submit' to know the allotment status.
How to Apply for the Influx Healthtech IPO?
- Step 1: Log in to your Kotak Securities Demat account: Log in to your Demat account to access IPO investments. Next, select the current IPO section.
- Step 2: Specify IPO details: Enter the number of lots and the price you wish to apply for.
- Step 3: Enter UPI ID After entering your UPI ID, click submit. This will place your bid with the exchange.
- Step 4: Mandate Notification: Your UPI app will receive a mandate notification to block funds.
- Step 5: Approve Request Your funds will be blocked once you approve the mandate request on your UPI.
This article is for informational purposes only and does not constitute financial advice. It is not produced by the desk of the Kotak Securities Research Team, nor is it a report published by the Kotak Securities Research Team. The information presented is compiled from several secondary sources available on the internet and may change over time. Investors should conduct their research and consult with financial professionals before making any investment decisions. Read the full disclaimer here.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing. Please read the SEBI-prescribed Combined Risk Disclosure Document before investing. Brokerage will not exceed SEBI’s prescribed limit.
Influx Healthtech IPO FAQs
What is the minimum lot size required for Influx Healthtech IPO?
The minimum lot size is 1200 shares and the investment required is ₹115200.
What is the price band of the Influx Healthtech IPO?
The price band of Influx Healthtech IPO is ₹91 to ₹96.
Where can I read more about Influx Healthtech business?
You can read more about Influx Healthtech and its IPO from the company’s red herring prospectus (RHP) here.
What is the Influx Healthtech IPO?
The Influx Healthtech Ltd IPO comprises a fresh issue and an offer for sale. The fresh issue consists of up to 50,00,400 equity shares, while the offer for sale is up to 11,00,400 equity shares.
When will the IPO of Influx Healthtech go live?
The IPO will open on June 18, 2025 and will close on June 20, 2025.
